Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure [3]

Blood

Volumn 103, Issue 5, 2004, Pages 1968-

  Versluys, Brigitta ^b   Bhattacharaya, Rajat ^b   Steward, Colin ^b   Comish, Jackie ^b   Oakhill, Anthony ^b   Goulden, Nick ^a  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BUSULFAN; CD33 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEFIBROTIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; URSODEOXYCHOLIC ACID;

CARDIOMYOPATHY; CHILD; CLINICAL ARTICLE; FEMALE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; VEIN OCCLUSION;

EID: 1442307426     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-10-3612     Document Type: Letter

References (4)

1. Wadleigh M, Ricahrdson P, Zahrleh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102:1578-1582.
2. Bearman S. Don't GO to VOD. Blood. 2003;102:1561-1562.
3. Webb DK, Harrison G, Stevens RF, et al. Relationships between age at diagnosis, clinical features, and outcome therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukaemia. Blood. 2001;98:1714-1720.
4. McCarthy AJ, Pitcher LA, Hann IM, Oakhill A. FLAG for refractory and high risk acute leukaemia in children. Med Paediatr Oncol. 1999;32:411-415.